Clinical Trial Update: A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors. [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 study evaluating NM-3, administered orally, in patients with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• NM-3

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Neoplasms | Phase 1 | Status: COMPLETED